ERBB2 and breast cancer: Our study identified significant associations between high UBE2C expression and aggressive tumour characteristics, including larger tumour size, high tumour grade, lymph node positivity, NPI poor prognostic groups, LVI positivity, hormone receptor (ER and PR) negativity, high expression of the proliferative marker Ki67, p53 and HER2 positivity, and the HER2-enriched intrinsic BC subtype in addition to poor patient outcomes.